Your browser version is outdated. We recommend that you update your browser to the latest version.

DeNovX is ...

National Institutes of Health Awards Second Grant to DeNovX

Posted 3/25/2016

On March 24, 2016 the NIH awarded DeNovX its second Phase I grant of $225,000 to advance the company's patented flow crystallization technology, which is under exclusive license from Illinois Institute of Technology.  The work targets the development of more cost effective and efficient methods of manufacturing crystalline pharmaceuticals that may help to overcome shortages of therapeutic drugs.  Hundreds of times each year, life-saving pharmaceuticals encounter a lack of availability, or drug shortage, which is most often attributed to quality control issues, manufacturing problems, and 

sometimes business and profitability decisions.  Such drug shortages negatively affect patients by causing treatment delays, medication errors from unsafe alternatives, and by increasing healthcare costs.  This work is sponsored by the NIH's National Center for Advancing Translational Sciences (NCATS), with the goal of a scale up demonstration for commercially relevant pharmaceuticals that include ketoconazole and crystalline epigallocatechin-3-gallate.  This effort builds on DeNovX's core skills in pharmaceutical physical formulation and development, as well as its robust patent portfolio that includes composition of matter coverage for pharmaceutical grade crystalline epigallocatechin-3-gallate as well as six additional issued patents in pharmaceutical discovery and production.